ARHGDIB Antibody

1. RhoGDIbeta overexpression led to downregulation of miR-200c, whereas miR-200c was able directly to target 3'-UTR of jnk2mRNA and attenuated JNK2 protein translation, which resulted in attenuation of Sp1mRNA and protein expression in turn, inhibiting Sp1-dependent MMP-2 transcription. PMID: 28846829
2. Binders to RhoGDI2 as a potential anti-cancer target have been first reported, and their weak interactions were depicted using NMR spectroscopy. PMID: 27721047
3. Delta19RhoGDIbeta has an apoptosisindependent role in the phorbol 12myristate 13acetate induced differentiation of THP1 cells to macrophages. PMID: 28260067
4. The caspase-3-cleaved RhoGDIbeta is a possible determinant to promote cancer spreading. PMID: 26919575
5. Our interpretation of these contradictions is that truncation and/or mutation of RhoGDI2 perturbs its conformation to expose a site that adventitiously binds FLNA and is not a bona-fide interaction. PMID: 26707877
6. Results show that RhoGDI2 suppresses bladder cancer metastatic colonization via negative regulation of RhoC activity, providing a rationale for the development of therapeutics that target RhoC signaling. PMID: 25516960
7. These findings indicate that RhoGDI2 repressed the activity of Rac1 and may be involved in the rearrangement of cytoskeleton in lung cancer cells. PMID: 25562149
8. Short hairpin RNA-mediated knockdown of RhoGDI2 induces the invasion and migration of lung cancer due to cross-talk with the PI3K/Akt pathway and MMP-9. PMID: 25266803
9. RhoGDI2 overexpression is associated with tumor growth, metastasis, and chemoresistance in gastric cancer. PMID: 24721928
10. Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma. PMID: 24788627
11. RhoGDI2 inhibits trophoblast cell migration, and this function may involve suppression of RAC1 activation. PMID: 24554735
12. 14-3-3sigma is a RhoGDI2-regulated gene that appears to be important for suppressing the chemoresistance of gastric cancer cells. PMID: 24185104
13. These results suggest that RhoGDIbeta has mitotic functions, including regulation of cytokinesis and bipolar spindle formation PMID: 23232495
14. Rictor regulates cell migration by suppressing RhoGDI2. PMID: 22777355
15. RhoGDI2 becomes rapidly phosphorylated at Ser31 in response to phorbol 12-myristate 13-acetate stimulation. Conventional type PKCalpha is responsible for this phosphorylation. PMID: 22469974
16. Expression of ARHGDIB variants 6a, 6b, and 6c appears to be restricted to cancer cells and normal placental tissue, suggesting that these variants possess cancer-specific functions. PMID: 23206989
17. The ARHGDIB is a lymphoid-specific intrinsic negative regulator of HIV-1 replication that acts by simultaneously inhibiting RhoA and Rac1 functions. PMID: 21936715
18. Results suggest that D4-GDI may function as a biphasic regulator of breast cancer progression and metastasis. PMID: 22674302
19. We delineate the mechanism by which RhoGDI2 promotes gastric cancer cell invasion and chemoresistance. In total, 47 differential protein spots were identified; 33 were upregulated, and 14 were downregulated by RhoGDI2 overexpression. PMID: 22364609
20. RhoGDI2 suppresses lung metastasis in mouse models by reducing the expression of isoforms V1 and V3 of the proteoglycan versican. RhoGDI2 suppressed metastasis by altering inflammation in the tumor microenvironment. PMID: 22406535
21. Overexpression of RhoGDI2 correlates with tumor progression in colorectal carcinoma. PMID: 21861235
22. activation of the Src family members and downstream signalling proteins are associated with a good prognosis in transitional cell carcinoma of the bladder, and activated Src has a positive relationship with RhoGD12. PMID: 22353809
23. PLCgamma plays a key role in RhoGDI2-mediated cisplatin resistance and cell invasion in gastric cancer cells. PMID: 21986528
24. identification of LyGDI as a binding partner of SHIP, associating inducibly with the SHIP/Grb2/Shc complex PMID: 21695085
25. This study has revealed that Rho GDP-dissociation inhibitor 2, Y-box binding protein 1, and the HSP70/90 organizing protein have a critical role to play in resistance to cyclin-depedent kinases inhibitor. PMID: 21067243
26. RhoGDI2 is likely to be involved in lung tumor malignancy and metastasis. PMID: 20596634
27. High LyGDI serum levels are associated with ovarian cancer. PMID: 20375790
28. RhoGDI2 is associated with c-Src in bladder tumors, where the expression of both is diminished as a function of stage. c-Src binds to and phosphorylates RhoGDI2 resulting in enhanced metastasis suppressive potency. Review. PMID: 20013033
29. These data suggest that D4-GDI of Rho family GTPase may be regulated during apoptosis through the caspase-3 mediated cleavage of the GDI protein. PMID: 11989976
30. Results demonstrate that modification of Rho guanine nucleotide dissociation inhibitor (GDI) 2 during apoptosis is often accompanied by their relocalisation between cellular compartments [Rho GDI 2 ] PMID: 12203895
31. the interaction of Vav1 and Ly-GDI creates a fine tuning mechanism for the regulation of intracellular signaling pathways leading to NFAT stimulation PMID: 12386169
32. RhoGDI2 has a role in progression of bladder cancer PMID: 15173088
33. RhoGDI2 may be implicated in the progress of malignancy. PMID: 17487395
34. One gene identified by microarray gene expression analysis, RhoGDI2, was tested and confirmed to be metastasis supressor gene; results from cells expressing RhoG-two molecular effectors of RhoGDI2 signaling were identified: endothelin-1 and Neuromedin U. PMID: 17826660
35. Rho-GDI beta has two roles: one that suppresses tumor progression by inhibiting migration and the other that stimulates it by enhancing Cox-2 expression PMID: 18006811
36. D4-GDI with two mutations (V68L & V69A) inhibited GDP dissociation from Rho in a dominant negative manner. It accelerates invasion via regulation of cytoskeletal machinery. PMID: 18037226
37. Transgenic mice with T cell-specific expression display altered cellular immunity against cytozoic pathogens PMID: 18689726
38. Overexpression of D4-GDI is associated with breast cancer. PMID: 19269969
39. RhoGDI2 metastasis inhibition works through Rho GTPases but via a mechanism distinct from inhibition of membrane association. PMID: 19276387
40. phosphorylation by Src enhances RhoGDI2 metastasis suppression and loss of Src relieves metastasis suppression in tumor cells that maintain RhoGDI2 expression. PMID: 19321744
41. RhoGDI2 is involved in gastric tumor growth and metastasis, and that RhoGDI2 may be a useful marker for tumor progression of human gastric cancer. PMID: 19351766
42. Results show that the established nerve invasion model and the consensus signature of perineural invasion could be instrumental in the identification of novel therapeutic targets of pancreatic cancer as exemplified by KIF14 and ARHGDIbeta. PMID: 19509238

显示更多

收起更多

HGNC: 679

OMIM: 602843

KEGG: hsa:397

STRING: 9606.ENSP00000228945

UniGene: Hs.504877